Cidara Therapeutics

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Cidara Therapeutics advances CD388 for high-risk flu prevention market

Cidara Therapeutics making progress with CD388 for flu prevention in high-risk patients Upcoming Phase III study to target high-risk comorbid and immune-compromised patients Focus on regulatory updates, commercial potential, and addressing market needs

Cidara Therapeutics excels in Phase IIb trial, secures funding for Phase III

Cidara Therapeutics is on track with promising Phase IIb results for CD388 against influenza. Strong financial backing from a successful public offering ensures funding for Phase III trials. Strategic plans in place for Phase III initiation, regulatory approvals, and commercialization opportunities.

Cidara Therapeutics advances CD388 with strong efficacy and financial backing

Cidara Therapeutics (CDTX) showcases strong performance with CD388's Phase III development progress and positive trial results, supported by financial strength and regulatory recognition. While facing challenges in scaling up manufacturing and expanding CD388's utility, CDTX has opportunities to tap into a large market and address broader public health needs. Investors should monitor CDTX's progress in Phase III trials, market expansion efforts, and the upcoming R&D Day for insights into the company's growth potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.